🚀 VC round data is live in beta, check it out!
Ambu Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ambu and similar public comparables like Carl Zeiss Meditec, Haemonetics, Autobio Diagnostics, LeMaitre Vascular and more.
Ambu Overview
About Ambu
Ambu AS provides medical technology solutions. The company’s business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.
Founded
1937
HQ
Employees
5.0K
Website
Financials (LTM)
EV
$3B
Ambu Financials
Ambu reported last 12-month revenue of $980M and EBITDA of $181M.
In the same LTM period, Ambu generated $594M in gross profit, $181M in EBITDA, and $97M in net income.
Revenue (LTM)
Ambu P&L
In the most recent fiscal year, Ambu reported revenue of $947M and EBITDA of $182M.
Ambu expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $980M | XXX | $947M | XXX | XXX | XXX |
| Gross Profit | $594M | XXX | $570M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $181M | XXX | $182M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $97M | XXX | $96M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ambu Stock Performance
Ambu has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Ambu's stock price is $10.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $0.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAmbu Valuation Multiples
Ambu trades at 2.7x EV/Revenue multiple, and 14.8x EV/EBITDA.
EV / Revenue (LTM)
Ambu Financial Valuation Multiples
As of April 27, 2026, Ambu has market cap of $3B and EV of $3B.
Equity research analysts estimate Ambu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ambu has a P/E ratio of 28.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.8x | XXX | 14.8x | XXX | XXX | XXX |
| EV/EBIT | 21.3x | XXX | 21.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | 4.7x | XXX | XXX | XXX |
| P/E | 28.0x | XXX | 28.3x | XXX | XXX | XXX |
| EV/FCF | 34.9x | XXX | 41.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ambu Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ambu Margins & Growth Rates
Ambu's revenue in the last 12 month grew by 11%.
Ambu's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Ambu's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ambu's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ambu Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 30% | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ambu Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ambu | XXX | XXX | XXX | XXX | XXX | XXX |
| Carl Zeiss Meditec | XXX | XXX | XXX | XXX | XXX | XXX |
| Haemonetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Autobio Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| LeMaitre Vascular | XXX | XXX | XXX | XXX | XXX | XXX |
| Double Medical Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ambu M&A Activity
Ambu acquired XXX companies to date.
Last acquisition by Ambu was on XXXXXXXX, XXXXX. Ambu acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ambu
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAmbu Investment Activity
Ambu invested in XXX companies to date.
Ambu made its latest investment on XXXXXXXX, XXXXX. Ambu invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ambu
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ambu
| When was Ambu founded? | Ambu was founded in 1937. |
| Where is Ambu headquartered? | Ambu is headquartered in Denmark. |
| How many employees does Ambu have? | As of today, Ambu has over 5K employees. |
| Is Ambu publicly listed? | Yes, Ambu is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Ambu? | Ambu trades under AMBU B ticker. |
| When did Ambu go public? | Ambu went public in 1993. |
| Who are competitors of Ambu? | Ambu main competitors are Carl Zeiss Meditec, Haemonetics, Autobio Diagnostics, LeMaitre Vascular. |
| What is the current market cap of Ambu? | Ambu's current market cap is $3B. |
| What is the current revenue of Ambu? | Ambu's last 12 months revenue is $980M. |
| What is the current revenue growth of Ambu? | Ambu revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Ambu? | Current revenue multiple of Ambu is 2.7x. |
| Is Ambu profitable? | Yes, Ambu is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ambu? | Ambu's last 12 months EBITDA is $181M. |
| What is Ambu's EBITDA margin? | Ambu's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Ambu? | Current EBITDA multiple of Ambu is 14.8x. |
| What is the current FCF of Ambu? | Ambu's last 12 months FCF is $77M. |
| What is Ambu's FCF margin? | Ambu's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Ambu? | Current FCF multiple of Ambu is 34.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.